UBS Group
TRAW icon

UBS Group’s Traws Pharma TRAW Stock Holding History

UBS Group’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.42K Sell
4,053
-3,669
-48% -$6.9K ﹤0.01% 8589
2025
Q4 		$8.73K Buy
7,722
+7,716
+128,600% +$17.2K ﹤0.01% 8338
2025
Q3 		$11 Sell
6
-3,000
-100% -$4.89K ﹤0.01% 10185
2025
Q2 		$4.45K Sell
3,006
-11,317
-79% -$18K ﹤0.01% 9262
2025
Q1 		$32.9K Buy
14,323
+13,532
+1,711% +$70.4K ﹤0.01% 7881
2024
Q4 		$7.02K Buy
791
+161
+26% +$896 ﹤0.01% 8509
2024
Q3 		$3.7K Sell
630
-3,313
-84% -$30.1K ﹤0.01% 8231
2024
Q2 		$44.1K Buy
3,943
+3,932
+35,745% +$63.4K ﹤0.01% 6789
2024
Q1 		$266 Sell
11
-295
-96% -$5.69K ﹤0.01% 8670
2023
Q4 		$5.71K Buy
306
+303
+10,100% +$5.16K ﹤0.01% 7765
2023
Q3 		$45 Sell
3
-223
-99% -$5.09K ﹤0.01% 9025
2023
Q2 		$6.67K Sell
226
-358
-61% -$9.63K ﹤0.01% 7346
2023
Q1 		$10.7K Buy
584
+5
+0.9% +$108 ﹤0.01% 7559
2022
Q4 		$9.41K Sell
579
-361
-38% -$6.81K ﹤0.01% 8653
2022
Q3 		$20K Buy
940
+928
+7,733% +$28K ﹤0.01% 7418
2022
Q2 		$0 Sell
12
-153
-93% -$5.16K ﹤0.01% 11050
2022
Q1 		$7K Buy
165
+68
+70% +$3.15K ﹤0.01% 8855
2021
Q4 		$6K Sell
97
-66
-40% -$5.31K ﹤0.01% 9305
2021
Q3 		$16K Buy
163
+6
+4% +$773 ﹤0.01% 7437
2021
Q2 		$27K Buy
157
+1
+0.6% +$226 ﹤0.01% 7048
2021
Q1 		$58K Sell
156
-2
-1% -$754 ﹤0.01% 6401
2020
Q4 		$28K Sell
158
-71
-31% -$8.24K ﹤0.01% 6699
2020
Q3 		$24K Sell
229
-103
-31% -$25.5K ﹤0.01% 6170
2020
Q2 		$71K Buy
332
+24
+8% +$3.67K ﹤0.01% 5585
2020
Q1 		$35K Buy
308
+44
+17% +$6.91K ﹤0.01% 6108
2019
Q4 		$38K Buy
264
+252
+2,100% +$47.1K ﹤0.01% 6519
2019
Q3 		$4K Buy
12
+2
+20% +$1.72K ﹤0.01% 7572
2019
Q2 		$10K Buy
10
+5
+100% +$6.88K ﹤0.01% 7084
2019
Q1 		$6K Buy
+5
New +$5.94K ﹤0.01% 7104
2018
Q4 		– Sell
-9
Closed -$25K – 8355
2018
Q3 		$25K Buy
9
+4
+80% +$10.2K ﹤0.01% 6677
2018
Q2 		$12K Buy
+5
New +$14.5K ﹤0.01% 7047
2018
Q1 		– Hold
0
– – – 7564
2017
Q4 		– Hold
0
– -$1K – 8145
2017
Q3 		– Sell
-1
Closed -$10.3K – 7601
2017
Q2 		$8K Buy
+1
New +$12.4K ﹤0.01% 6931
2017
Q1 		– Sell
-1
Closed -$7K – 8039
2016
Q4 		$7K Buy
+1
New +$14.8K ﹤0.01% 7101
2016
Q3 		– Hold
0
– -$7K – 7977
2016
Q2 		– Hold
0
– – – 6993
2016
Q1 		– Sell
-1
Closed -$31.7K – 6503
2015
Q4 		$47K Buy
+1
New +$74.1K ﹤0.01% 5879
2015
Q3 		– Hold
0
– – – 6974
2015
Q2 		– Hold
0
– – – 8092
2015
Q1 		– Hold
0
– – – 8601
2014
Q4 		– Hold
0
– – – 8162

Other funds holding TRAW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's TRAW Position: Q1 2026 in Review

UBS Group reduced its Traws Pharma (TRAW) stake by 48% in Q1 2026, selling an estimated $6.9K and leaving 4,053 shares worth $7.42K. The position accounts for ﹤0.01% of the portfolio, ranked #8589.

UBS Group first reported a position in TRAW in Q4 2015 and has held it in 34 quarters since. The position peaked at $71K in Q2 2020. 28 funds tracked by Wall St. Rank hold TRAW as of Q1 2026.

  • UBS Group held 4,053 shares of Traws Pharma worth $7.42K as of Q1 2026.
  • UBS Group sold 3,669 Traws Pharma shares in Q1 2026, an estimated $6.9K.
  • Traws Pharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8589 holding.
  • UBS Group first reported a position in Traws Pharma in Q4 2015 and has held it in 34 quarters since.
  • UBS Group's Traws Pharma position peaked at $71K in Q2 2020.
  • 28 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.